Answers are grounded in this paper and cite their sources.
The emergence of drug resistance in human immunodeficiency virus type 1 (HIV-1) may limit the clinical benefits of antiretroviral therapy. There is no objective evidence that the risk of drug resistance is greater in resource-limited settings than in the developed world. Treatment programmes will be most successful at preventing the spread of drug resistance if they provide healthcare infrastructures to maximize the effectiveness of antiretroviral therapy through the use of potent and convenient combination regimens that achieve durable suppression of HIV-1 replication.
No takes yet. Share an insight, caveat, or question.
Daniel R. Kuritzkes (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: